Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902062 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL5987924 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7773873 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL783035 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499157 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7865088 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL23070514 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL133039 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499165 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL130279 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1132370-A2 | Process for producing n-substituted polyhydroxy nitrogen-containing heterocyles | MONSANTO COMPANY (US) | 2001-09-12 | — | — | EP | claimed |
| US-20010019837-A1 | PROCESS FOR MICROBIALLY OXIDIZING N-SUBSTITUTED GLUCAMINES | GRABNER ROY WALTER (US) | 2001-09-06 | — | — | US | claimed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0477160-A1 | Process for producing N-substituted-1-deoxynojirimycin | MONSANTO COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| EP-3574909-B1 | POLYELECTROLYTE MULTILAYER COMPRISING SILVER FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | IMBED BIOSCIENCES INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250375394-A1 | METHODS AND COMPOSITIONS FOR MODIFYING MUCOUS MEMBRANES | ABBOTT NICHOLAS L (US) | 2025-12-11 | — | — | US | disclosed |
| US-12409247-B2 | Methods and compositions for wound healing | IMBED BIOSCIENCES INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250221934-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250221933-A1 | MICRONIZED LIPIDS | MCAL THERAPEUTICS INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250205278-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | ABBOTT NICHOLAS L (US) | 2025-06-26 | — | — | US | disclosed |
| US-12214079-B2 | Micronized lipids | MCAL THERAPEUTICS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
| US-5196454-A | METHOD OF TREATING DISORDERS OF THE DOPAMINERGIC SYSTEMS USING 2,5-DIAMINOTETRALINES | BOEHRINGER INGELHEIM KG (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5178669-A | COMPOSITION FOR REVERSIBLE THERMAL RECORDING MEDIA | TOPPAN PRINTING CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0418399-A1 | COMPOSITION FOR REVERSIBLE THERMAL RECORDING MEDIUM | Toppan Printing Co., Ltd. (JP) | 1991-03-27 | — | — | EP | disclosed |
| EP-0402923-A2 | 2,5-Diaminotetralines, process for their preparation and their use as medicine | BOEHRINGER INGELHEIM KG (DE) | 1990-12-19 | — | — | EP | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| US-4228187-A | ANTISPASMODIC, VASODILATOR, HYPOTENSIVE AGENTS | CONTINENTAL PHARMA (BE) | 1980-10-14 | — | — | US | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000805-A1 | METHODS AND COMPOSITIONS FOR WOUND HEALING | PCNA, ARG1, PLOD3 | MAOA 941/4885HTR2A 1309/4885CYP2A6 4646/4885 |
| US-20250221933-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAOA 1363/4885HTR2A 1413/4885CYP2A6 482/4885 |
| US-20250221934-A1 | MICRONIZED LIPIDS | SGMS1, SGMS2, MGLL | MAOA 1363/4885HTR2A 1413/4885CYP2A6 482/4885 |
| US-12214079-B2 | Micronized lipids | SGMS1, SGMS2, MGLL | MAOA 1363/4885HTR2A 1413/4885CYP2A6 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.